Last reviewed · How we verify
TAK-875 and Glimepiride
TAK-875 and Glimepiride is a Small molecule drug developed by Takeda. It is currently in Phase 1 development. Also known as: Amaryl.
At a glance
| Generic name | TAK-875 and Glimepiride |
|---|---|
| Also known as | Amaryl |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes (PHASE3)
- Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus (PHASE2)
- TAK-875 Glimepiride Drug-Interaction Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-875 and Glimepiride CI brief — competitive landscape report
- TAK-875 and Glimepiride updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about TAK-875 and Glimepiride
What is TAK-875 and Glimepiride?
TAK-875 and Glimepiride is a Small molecule drug developed by Takeda.
Who makes TAK-875 and Glimepiride?
TAK-875 and Glimepiride is developed by Takeda (see full Takeda pipeline at /company/takeda).
Is TAK-875 and Glimepiride also known as anything else?
TAK-875 and Glimepiride is also known as Amaryl.
What development phase is TAK-875 and Glimepiride in?
TAK-875 and Glimepiride is in Phase 1.
Related
- Manufacturer: Takeda — full pipeline
- Also known as: Amaryl
- Compare: TAK-875 and Glimepiride vs similar drugs
- Pricing: TAK-875 and Glimepiride cost, discount & access